CAM
TAK icon

Close Asset Management’s Takeda Pharmaceutical TAK Stock Holding History

Close Asset Management’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-441
Closed -$8K – 226
2021
Q1 		$8K Buy
+441
New +$7.93K ﹤0.01% 195

Other funds holding TAK

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Close Asset Management's TAK Position: Q2 2021 in Review

Close Asset Management sold out of Takeda Pharmaceutical (TAK) in Q2 2021, closing a stake of 441 shares — an estimated $8K sold.

Close Asset Management first reported a position in TAK in Q1 2021 and held it in 1 quarter. The position peaked at $8K in Q1 2021. 304 funds tracked by Wall St. Rank hold TAK as of Q2 2021.

  • Close Asset Management reported no remaining Takeda Pharmaceutical position as of Q2 2021 after selling out during the quarter.
  • Close Asset Management sold 441 Takeda Pharmaceutical shares in Q2 2021, an estimated $8K.
  • Close Asset Management first reported a position in Takeda Pharmaceutical in Q1 2021 and held it in 1 quarter.
  • Close Asset Management's Takeda Pharmaceutical position peaked at $8K in Q1 2021.
  • 304 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2021.

Based on Close Asset Management's 13F filing for Q2 2021, filed 27 Jul 2021.